Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
Title:
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
Author:
Nowakowski, Grzegorz S. Yoon, Dok Hyun Mondello, Patrizia Joffe, Erel Peters, Anthea Fleury, Isabelle Greil, Richard Ku, Matthew Marks, Reinhard Kim, Kibum Zinzani, Pier Luigi Trotman, Judith Sabatelli, Lorenzo Waltl, Eva E. Winderlich, Mark Sporchia, Andrea Kurukulasuriya, Nuwan C. Cordoba, Raul Hess, Georg Salles, Gilles